Parag Garhyan

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof Kazda, Ying Ding, Ronan P. Kelly et al. · Diabetes Care · 2015 · 210 citations · Full text

Dose correspondence between olanzapine long-acting injection and oral olanzapine

Holland C. Detke, Fangyi Zhao, Parag Garhyan et al. · International Clinical Psychopharmacology · 2010 · 184 citations

Olanzapine Long-acting Injection, Oral Olanzapine, Psychiatry +13

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Cristina B. Guzmán, Xiaotian Michelle Zhang, Rong Liu et al. · Diabetes Obesity and Metabolism · 2017 · 162 citations

Short‐term administration of the glucagon receptor antagonist <scp>LY2409021</scp> lowers blood glucose in healthy people and in those with type 2 diabetes

Raymond P. Kelly, Parag Garhyan, Eyas Raddad et al. · Diabetes Obesity and Metabolism · 2015 · 107 citations

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Olivier Bénichou, Tamer Coşkun, Malgorzata D. Gonciarz et al. · Cell Metabolism · 2023 · 87 citations